Brown Advisory’s Exagen XGN Stock Holding History

Brown Advisory’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,323	Closed	-$229K	–	1119
2020 Q4	$229K	Sell	17,323 -4,602	-21%	-$65K	﹤0.01%	939
2020 Q3	$238K	Buy	+21,925	New	+$282K	﹤0.01%	865

Other funds holding XGN

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory's XGN Position: Q1 2021 in Review

Brown Advisory sold out of Exagen (XGN) in Q1 2021, closing a stake of 17,323 shares — an estimated $229K sold.

Brown Advisory first reported a position in XGN in Q3 2020 and held it in 2 quarters. The position peaked at $238K in Q3 2020. 57 funds tracked by Wall St. Rank hold XGN as of Q1 2021.

Brown Advisory reported no remaining Exagen position as of Q1 2021 after selling out during the quarter.
Brown Advisory sold 17,323 Exagen shares in Q1 2021, an estimated $229K.
Brown Advisory first reported a position in Exagen in Q3 2020 and held it in 2 quarters.
Brown Advisory's Exagen position peaked at $238K in Q3 2020.
57 funds tracked by Wall St. Rank held Exagen as of Q1 2021.

Based on Brown Advisory's 13F filing for Q1 2021, filed 14 May 2021.